Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease

Journal of Neuroscience Methods
Pratibha Mehta LuthraRam Raghubir

Abstract

Parkinson's disease (PD) exhibits symptoms of motor dysfunction such as tremor, akinesia and rigidity. Agents that selectively disrupt or destroy catecholaminergic systems, such as reserpine, methamphetamine, 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, have been used to develop PD models and to study the animal behavior like catalepsy, akinesia, swim-test, etc. The major apprehension while working with these chemicals is their irreversible neuro-toxic effect. Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS). Measuring catalepsy and akinesia in the treated mice monitored the haloperidol-induced EPS. Alternatively, swimming disability was tested as a new parameter to monitor haloperidol-induced EPS. The results showed that the restoration of swimming disability in haloperidol-induced L-dopa and caffeine pre-treated mice could be used as pre-clinical model to study PD.

References

Sep 1, 1989·Pharmacology, Biochemistry, and Behavior·F B WeihmullerJ P Bruno
Feb 15, 1988·Neuroscience Letters·F B WeihmullerJ P Bruno
Feb 1, 1987·Journal of the Neurological Sciences·G A DonnanP Rowe
Jun 1, 1974·European Journal of Pharmacology·B Costall, R J Naylor
Sep 1, 1993·Pharmacology, Biochemistry, and Behavior·P M CarveyJ Z Fields
Apr 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·E AllevaL Aloe
Jul 1, 1997·Neuroscience and Biobehavioral Reviews·W J Schmidt, B D Kretschmer
Nov 5, 1997·Trends in Pharmacological Sciences·P J RichardsonP G Jenner
May 24, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·A D Crocker, K M Hemsley
Jun 23, 2001·Pharmacology, Biochemistry, and Behavior·K R PowellS G Holtzman
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M L WadenbergS Kapur
Feb 26, 2004·The Annals of Pharmacotherapy·Oscar P Dall'IgnaDiogo R Lara
May 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Mark E JacksonBita Moghaddam
Aug 2, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alexander KuzminBertil B Fredholm
Jan 13, 2006·The Journal of Biological Chemistry·Kotaro HattoriShigeki Yuasa
Jun 26, 2007·Physiology & Behavior·Gilberto FisoneEmanuela Santini

❮ Previous
Next ❯

Citations

May 29, 2013·Pharmacology & Therapeutics·Elaine Cristina Gavioli, Girolamo Calo'
Dec 26, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Shadab MdJaved Ali
Apr 20, 2018·Current Drug Discovery Technologies·Rajalakshmi RukmangathenPrasanna Raju Yalavarthi
May 9, 2015·Expert Review of Neurotherapeutics·Gulam MustafaJaved Ali
Apr 6, 2021·The European Journal of Neuroscience·Isabelle WakuAmanda R de Oliveira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.